DISCUSSION OF PAUL LUGARDS INNOVATION IS KING; OR IS IT? Eric van - - PowerPoint PPT Presentation

discussion of paul lugard s innovation is king or is it
SMART_READER_LITE
LIVE PREVIEW

DISCUSSION OF PAUL LUGARDS INNOVATION IS KING; OR IS IT? Eric van - - PowerPoint PPT Presentation

DISCUSSION OF PAUL LUGARDS INNOVATION IS KING; OR IS IT? Eric van Damme CentER and TILEC Tilburg University 27 november 2012 Competition Workshop 1 THIS DISCUSSION Short summary of Pauls short paper A clarifying question


slide-1
SLIDE 1

DISCUSSION OF PAUL LUGARD’S “INNOVATION IS KING; OR IS IT?”

Eric van Damme CentER and TILEC Tilburg University

27 november 2012 Competition Workshop 1

slide-2
SLIDE 2

THIS DISCUSSION

  • Short summary of Paul’s short paper
  • A clarifying question
  • Some more general observations
  • Conclusion

27 november 2012 Competition Workshop 2

slide-3
SLIDE 3

PAUL’S PAPER (WITH CARDWELL)

  • Innovation is very important for welfare
  • One would expect that, in the review of business

transactions, there to be a lot of attention to: what is the effect on innovation?

  • In the EU that is not the case; in EUMR given little

attention, framework not very developed

  • Suggestions for framework; brief discussion of cases
  • Better framework in the US
  • Need for reform in the EU

27 november 2012 Competition Workshop 3

slide-4
SLIDE 4

QUESTION ON CLASSIFICATION

  • For EUMR, Paul distinguishes 3 categories of cases:

– The transaction reduces innovation

  • Merging R&D labs, merging leader and follower

– The transaction reduces competition and as a result of that might reduce innovation

  • Merger enhances market power, and…

– The transaction produces dynamic efficiencies, hence, improves innovation, which may be sufficient to offset “static objections”

  • As discussed in paper by Reinhilde (verifiability issues)
  • Example from US: merger to monopoly (narrow market)
  • The distinction between 1 and 2 not so clear to me

– Also: ex post review of that US decision?

27 november 2012 Competition Workshop 4

slide-5
SLIDE 5

3 MORE GENERAL OBSERVATIONS

  • The issue is broader than the EUMR

– Paul mentions innovation has been important in 102 cases, but suggests less important in 101 – However, health care sector NL; VWS <-> NMa

  • How important is this dimension in total?

– Compare to well functioning patent system – Well documented that uncertainty about patent validity (abuse by NPEs) limits innovation

  • Catherine Tucker; Patent trolls and Technology Diffusion
  • Economic literature still small

– Theory: Segal & Whinston: Comp Policy & Innovation – Empirical: Cassiman et al (paper Reinhilde)

27 november 2012 Competition Workshop 5

slide-6
SLIDE 6

CONCLUSION

  • Broad agreement between Paul and Reinhilde
  • Is there sufficient empirical evidence (EU vs US)

and a sufficiently strong academic foundation to support a review or overhaul of the framework underlying the EUMR?

27 november 2012 Competition Workshop 6